

APR 22 2004

page 1/2

510(k) Summary
AMS Apogee™ Vault Suspension System

510(k) Number K040537

Date of Summary Preparation:
March 1, 2003

Submitter/Contact Person:
Elsa A. Linke
Regulatory Affairs Specialist
American Medical Systems
10700 Bren Rd. W
Minnetonka, MN 55343

Phone: (952) 930-6000
Fax: (952) 930-6496

Device Name and Classification:
Trade Name: AMS Apogee™ Vault Suspension System
Common/Usual Name: Surgical Mesh
Classification Name: Surgical Mesh, polymeric
Product Code: **OTP**
Classification: Class II

Manufacturing Location:
American Medical Systems, Inc.
10700 Bren Rd. West
Minnetonka, MN 55343

Predicate Devices:
AMS Sparc Sling System – K011251, K013355, K020663
AMS Monarc Sling System – K023516
AMS BioArc – K030123
AMS Large Pore Polypropylene Mesh – K033636
IVS Tunneller – K010035

Indications for Use:
The Apogee™ Vault Suspension System is intended for use in vaginal vault suspension to treat pelvic organ prolapse.

Device Description:
The Apogee™ Vault Suspension System consists of needles and connectors used to pass a polypropylene mesh for support of the vaginal vault.

Summary of Testing
The mesh used in the Apogee™ Vault Suspension System has been tested in accordance with FDA's Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh and has been shown to be equivalent to the listed predicate devices. In addition, the other components have demonstrated

K040537 page 2/2

substantial equivalence to the predicate devices in terms of mechanical performance and biocompatibility.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Ms. Elsa A. Linke
Regulatory Affairs Specialist
American Medical Systems
10700 Bren Road West
MINNETONKA MN 55343

SEP 28 2012

Re: K040537
Trade/Device Name: Apogee™ Vault Suspension System
Regulation Number: 21 CFR 878.3300
Regulation Name: Surgical mesh
Regulatory Class: II
Product Code: OTP
Dated: March 1, 2004
Received: March 2, 2004

Dear Ms. Linke:

This letter corrects our substantially equivalent letter of April 22, 2004.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Benjamin R. Fisher". The signature is fluid and cursive, with the first name "Benjamin" being the most prominent part.

Benjamin R. Fisher, Ph.D.
Director

Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number (if known): K040537

Device Name: Apogee™ Vault Suspension System

Indications For Use: The Apogee™ Vault Suspension System is intended for use in vaginal vault suspension to treat pelvic organ prolapse.

Prescription Use X
(Per 21 CFR 801 Subpart D)

AND/OR

Over-The Counter Use
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Miriam C. Provost
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

Page 1 of

510(k) Number K040537